Experimental Evaluation of Application of the Vaccine Strain Yersinia pestis EV NIIEG in Combination with Immune-Modulators

Abstract. Objective of the work was to conduct a comparative assessment of the immune-modulating effect of the combined use of Yersinia pestis EV NIIEG vaccine strain with Polyoxidonium and Ingaron preparations on a BALB/c mouse model.

Materials and methods. Mice of the BALB/c line were immunized subcutaneously with Yersinia pestis EV NIIEG culture at a dose of 2.5 10⁴ m.c. (1st group), in combination with Ingaron at a dose of 150 IU (2nd group) or with Polyoxidonium at a dose of 4 мg (3rd group), the 4th group is intact mice. On days 3, 7, 21 and 90 after immunization, the subpopulation composition of lymphocytes, the production of mediators of the cellular response (INF-ɣ and IL-10), the titers of specific antibodies to the capsular antigen of plague microbe (F1), the nuclear apparatus of lymphocytes, and the nature of histological changes in the organs of mice were determined. Characterization of immunogenic (protective) activity of the combined use of Y. pestis EV NIIEG with immune-modulators against Y. pestis 231 in experiments on BALB/c mice was performed on the 21st day after immunization through determining the number of dead animals and their average life expectancy.

Results and discussion. The combined administration of Y. pestis EV NIIEG vaccine strain with Polyoxidonium or Ingaron to experimental animals allowed us to establish differences in the response of the immune system of biomodels, due to the mechanism of action of a specific immune-modulator. It has been established that both Polyoxidonium and Ingaron combined with Y. pestis EV NIIEG enhance the response of immune-competent cells in experimental animals, contribute to the activation of the humoral response and the production of mediators of the cellular response, do not have a damaging effect on the tissue of the macroorganism. At the same time, the efficacy of using combined vaccination of Y. pestis EV NIIEG with immune-modulators in the inoculation test is confirmed for Polyoxidonium only.

1. Kostinova M.P., Solov’eva I.L., editors. Immunomodulators and Vaccination. M.: 4Mpress; 2013. 272p.

2. Ponomareva T.S., Deryabin P.N., Tugambaev T.I., Mel’nikova N.N., Adambekov D.A. Immunomodulation as a way to increase the immunogenicity of live plague vaccine. Vestnik KGMA im. I.K. Akhunbaeva [Bulletin of the KSMA named after I.K. Akhunbaeva]. 2015; 3:95–7.

3. Bogacheva N.V., Okhapkina V.Yu., Pyatkova N.V., Fedotov A.K., Kucherenko A.S. Experimental study of the effect of immunomodulators on the efficacy of a live dry brucella vaccine application. Epidemiologiya i Vaktsinoprofilaktika [Epidemiology and Vaccinal Prevention]. 2016; 15(2):84–92. DOI: 10.31631/20733046-2016-15-2-84-92.

4. Pinegin B.V., Nekrasov A.V., Khaitov R.M. Polyoxidonium immunomodulator: mechanisms of action and aspects of clinical use.Tsitokiny i Vospalenie [Cytokines and Inflammation]. 2004; 3:41–7.

5. Karaulov A.V., Evsegneeva I.V. Modern approaches to vaccine prevention of influenza. Vaktsinatsiya [Vaccination]. 2011; 1(1):43–52.

6. Kravtsov A.L., Klyueva S.N., Bugorkova S.A. The effect of immunomodulators on the reactivity of immune system cells in the simulation of anti-tularemia vaccine process. Epidemiologiya i Vaktsinoprofilaktika [Epidemiology and Vaccinal Prevention]. 22016; 15(3):94–101. DOI: 10.31631/2073-3046-2016-15-3-94-101.

7. Kiselev O.I., Stukova M.A., Namgaladze A.D., Golovacheva E.G., Erofeeva M.K. A method of preventing influenza by the combined use of interferon gamma and inactivated influenza vaccine. RF patent No 2546540. Publ. 04/10/2015 Bul No. 10.

8. Manina I.V., Mikhailova I.N., Kozlov A.M., Baryshnikov A.Yu. A method for increasing the immunogenicity of whole cell cancer vaccines. The patent of the Russian Federation № 2458120. Publ. 08/10/2012. Bul №22.

9. Ponomareva, T.S., Deryabin, P.N., Karal’nik, B.V., Tugambaev T.I., Atshabar B.B., Denisova T.G., Zakaryan S.B., Mel’nikova N.N. The effect of polyoxidonium on the immunogenic and protective activity of live plague vaccine. Immunologiya [Immunology]. 2014; 35(5):286–90.

10. Verlan N. V. Interferon usage: immunological and clinical aspects. Tsitokiny i Vospalenie [Cytokines and Inflammation]. 2016; 15(1):12–21.

11. Amedei A., Niccolai E., Marino L., D’Elios M.M. Role of immune response in Yersinia pestis infection. J. Infect. Dev. Ctries. 2011; 5(9):628–39. DOI: 10.3855/jidc.1999.

12. Williamson E.D. The role of immune correlates and surrogate markers in the development of vaccines and immunotherapies for plague. Adv. Prev. Med. 2012; 2012:365980. DOI: 10.1155/2012/365980.

13. Zhang X., Qi Z., Du Z., Bi Y., Zhang Q., Tan Y., Yang H., Xin Y., Yang R., Wang X. A live attenuated strain of Yersinia pestis ДyscB provides protection against bubonic and pneumonic plagues in mouse model. Vaccine. 2013; 31(22):2539–42. DOI: 10.1016/j.vaccine.2013.03.054

14. Klyueva S.N., Shchukovskaya T.N. The influence of newgeneration adjuvants in vitro on the production of cytokines by blood cells of the vaccinated against plague individuals. Rossiyskiy Immunologicheskiy Zhurnal [Russian Immunological Journal]. 2015; 9(2):201–208.

15. Korzhevsky D.E., Gilyarov A.V. Fundamentals of histological technology. St. Petersburg: Publishing House SpetsLit LLC; 2010. 95 p.

16. Howell W.M., Black D.A. Controlled silver-staining of nucleolus organizer regions with a protective colloidal developer: a 1-step method. Experientia. 1980; 36:1014–5. DOI: 10.1007/BF01953855.

17. Khaitov R.M. Immunology. M.: GEOTAR-Media; 2006. 255 p.

18. Crocker J., Nar P. Nucleolar organizer regions in lymphomas. J. Pathol. 1987; 151:111–8. DOI: 10.1002/path.1711510203.

19. Bugorkova S.A., Shchukovskaya T.N., Kurylina A.F. The nucleoli apparatus of lymphocytes as an indicator of the functional activity of lymphoid organs in the preclinical evaluation of vaccines. Problemy Osobo Opasnykh Infektsii [Problems of Particularly Dangerous Infections]. 2015; 2:75–8. DOI: 10.21055/0370-10692015-2-75-78.